- Lipocine Announces Financial Results For The Year Ended December 31, 2020
- Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference
- Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis
- Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
- Lipocine to Present at Two Upcoming Investor Conferences
- Lipocine Closes Underwritten Public Offering Of Common Stock
- Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock
- Lipocine Announces Launch Of Public Offering Of Common Stock
Lipocine Inc (LPCN:NAQ) closed at 1.41, 187.76% above the 52 week low of 0.49 set on Apr 20, 2020.
0.49Apr 20 20202.42Jan 22 2021
Markit short selling activity
|Market cap||122.72m USD|
|EPS (TTM)||-0.4017 |
Data delayed at least 15 minutes, as of Apr 20 2021 21:00 BST.